Polymorphisms in the human paraoxonase (PON1) promoter

被引:153
作者
Brophy, VH
Hastings, MD
Clendenning, JB
Richter, RJ
Jarvik, GP
Furlong, CE
机构
[1] Univ Washington, Dept Genet, Seattle, WA 98195 USA
[2] Univ Washington, Dept Biotechnol & Med, Seattle, WA 98195 USA
[3] Univ Washington, Div Med Genet, Seattle, WA 98195 USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
来源
PHARMACOGENETICS | 2001年 / 11卷 / 01期
关键词
PON1; promoter polymorphism; atherosclerosis; gene expression; organophosphorus insecticides;
D O I
10.1097/00008571-200102000-00009
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Paraoxonase (PON1) is a protein component of high-density lipoprotein (HDL) particles that protects against oxidative damage to both low-density lipoprotein and HDL and detoxifies organophosphorus pesticides and nerve agents. A wide range of expression levels of PON1 among individuals has been observed. We examined the promoter region of PON1 for genetic factors that might affect PON1 activity levels. We conducted a deletion analysis of the PON1 promoter region in transient transfection assays and found that cell-type specific promoter elements for liver and kidney are present in the first 200 bp upstream of the coding sequence. Sequence analysis of DNA from a BAC clone and a YAC clone identified five polymorphisms in the first 1000 bases upstream of the coding region at positions -108, -126, -162, -832 and -909. Additionally, the promoter sequences of two individuals expressing high levels of PON1 and two individuals expressing low levels of PON1 were analysed, The two polymorphisms at -126 and -832 had no apparent effect on expression level in the reporter gene assay. The polymorphisms at position -909, -162 (a potential NF-1 transcription factor binding site) and -108 (a potential SP1 binding site) each have approximately a two-fold effect on expression level. The expression level effects of the three polymorphisms appear not to be strictly additive and may depend on context effects. Pharmacogenetics 11:77-84 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
[1]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[2]  
BECKLER GEA, 1996, PROTOCOLS APPL GUIDE, P168
[3]  
Blatter Garin Marie-Claude, 1997, Journal of Clinical Investigation, V99, P62
[4]   Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype [J].
Brophy, VH ;
Jarvik, GP ;
Richter, RJ ;
Rozek, LS ;
Schellenberg, GD ;
Furlong, CE .
PHARMACOGENETICS, 2000, 10 (05) :453-460
[5]   CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors [J].
Clegg, AO ;
Ashton, LJ ;
Biti, RA ;
Badhwar, P ;
Williamson, P ;
Kaldor, JM ;
Stewart, GJ .
AIDS, 2000, 14 (02) :103-108
[6]   Structural organization of the human PON1 gene [J].
Clendenning, JB ;
Humbert, R ;
Green, ED ;
Wood, C ;
Traver, D ;
Furlong, CE .
GENOMICS, 1996, 35 (03) :586-589
[7]   The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin [J].
Davies, HG ;
Richter, RJ ;
Keifer, M ;
Broomfield, CA ;
Sowalla, J ;
Furlong, CE .
NATURE GENETICS, 1996, 14 (03) :334-336
[8]   A PITFALL OF USING A 2ND PLASMID TO DETERMINE TRANSFECTION EFFICIENCY [J].
FARR, A ;
ROMAN, A .
NUCLEIC ACIDS RESEARCH, 1992, 20 (04) :920-920
[9]   Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response [J].
Feingold, KR ;
Memon, RA ;
Moser, AH ;
Grunfeld, C .
ATHEROSCLEROSIS, 1998, 139 (02) :307-315
[10]  
Furlong CE, 1998, NEUROTOXICOLOGY, V19, P645